Incyte INCY
NASDAQ INCY
$126.75 -1.25 (-0.98%)
As of: Sep 4, 2026 · 3:59 PM EDT

Incyte (INCY) Other Non-Current Liabilities (2013 - 2026)

Incyte's (INCY) quarterly Other Non-Current Liabilities came in at $124.5 million in Q2 2026, down 30.79% YoY from $179.9 million in Q2 2025, and down 1.64% on a QoQ basis from $126.6 million in Q1 2026.

Analysis

Incyte (INCY) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends

Incyte (INCY) has 14 years of Other Non-Current Liabilities data on file, last reported at $124.5 million in Q2 2026.

  • Quarterly Other Non-Current Liabilities fell 30.79% year-over-year to $124.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $124.5 million (down 30.79% YoY) and the FY2025 annual result came in at $165.3 million, down 1.36% from the prior year.
  • Other Non-Current Liabilities retreated to $124.5 million in Q2 2026, from $126.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $204.1 million in Q1 2022 to a low of $124.5 million in Q2 2026.
  • A 5-year average of $170.2 million and a median of $171.5 million in 2022 frame the typical range for Other Non-Current Liabilities.
  • Annual changes were most pronounced in 2025 — Other Non-Current Liabilities climbed 14.71% — and 2026, when it slumped 30.79%.
  • Tracing INCY's Other Non-Current Liabilities over 5 years: stood at $184.5 million in 2022, then slipped by 5.9% to $173.6 million in 2023, then decreased by 3.48% to $167.5 million in 2024, then declined by 1.36% to $165.3 million in 2025, then declined by 24.66% to $124.5 million in 2026.
  • The last three Other Non-Current Liabilities figures came in at $124.5 million (Q2 2026), $126.6 million (Q1 2026), and $165.3 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Incyte 25.44 Bn 20.91 Bn 1.57 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 124.52 Mn
Mar 31, 2026 126.59 Mn
Dec 31, 2025 165.27 Mn
Sep 30, 2025 171.18 Mn
Jun 30, 2025 179.91 Mn
Mar 31, 2025 175.59 Mn
Dec 31, 2024 167.54 Mn
Sep 30, 2024 166.67 Mn
Jun 30, 2024 156.85 Mn
Mar 31, 2024 164.84 Mn
Dec 31, 2023 173.58 Mn
Sep 30, 2023 170.19 Mn
Jun 30, 2023 179.49 Mn
Mar 31, 2023 180.83 Mn
Dec 31, 2022 184.46 Mn
Sep 30, 2022 171.81 Mn
Jun 30, 2022 200.09 Mn
Mar 31, 2022 204.13 Mn
Dec 31, 2021 206.99 Mn
Sep 30, 2021 213.78 Mn